Business
TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
Dundee Corporation maintains 5% stake in company developing a revolutionary treatment for Al...
About this update from Dundee Corporation Class A
[{"type":"text","content":"\n\n\n\n\nDundee Corporation maintains 5% stake in company developing a revolutionary treatment for Alzheimer's Disease\n\nTORONTO and SINGAPORE, March 4, 2013 /CNW/ - TauRx Pharmaceuticals Ltd. (\"TauRx\") announced today the receipt of an equity investment of USD10.5m from Dundee Corporation of Toronto (\"Dundee\"). The investment will be used by TauRx primarily to support the on-going program of three Phase 3 clinical trials of LMTX™, its novel compound currently in development as a disease-modifying treatment for Alzheimer's Disease (\"AD\") and behavioural-variant Fronto-Temporal Dementia (\"bvFTD\").\nDundee made its initial investment of USD20m in TauRx in September 2011. Ned Goodman, President and Chief Executive Officer of Dundee, said: \"TauRx has made good use of our initial investment, gaining regulatory clearance to initiate its Phase 3 study program for LMTX™ and establishing a network of experienced service providers to support the studies. With the first patients now being enrolled into each of the three studies, and with the recent substantial strategic investment from the Genting Berhad group, this seems a highly opportune time to exercise the option we were granted by TauRx at the time of the initial investment and maintain Dundee's 5% interest in this commercially and scientifically promising company.\"\nProfessor Claude Wischik, Executive Chairman and Co-Founder of TauRx, said: \"It is particularly gratifying to receive this follow-on investment from Dundee. It made its initial investment at a time of critical importance to the development of both TauRx and our Tau aggregation inhibitor, LMTX™, and we see this additional investment of USD10.5m as a welcome vote of confidence in the commercial potential of our technology from a highly experienced investor. We continue to believe strongly that Tau aggregation inhibition is the most promising approach to the long-term treatment of AD and other Tau-opathies such as bvFTD. With expanding patient populations throughout the world due to an aging population, and with products based on beta-amyloid clearance still producing disappointing results in clinical studies, it is now critically important for healthcare systems, patients, their families and their careers to bring an effective treatment for these devastating diseases to market.\" \nAbout T...